Cognitive Enhancement in Schizophrenia. Pharmacological and Cognitive Remediation Approaches

Psychiatric Clinics of North America

Volumn 35, Issue 3, 2012, Pages 683-698

  Harvey, Philip D ^a   Bowie, Christopher R ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

Cognitive enhancement; Pharmacological treatment; Schizophrenia

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; AMPAKINE; AMPHETAMINE; ARIPIPRAZOLE; ATOMOXETINE; BUSPIRONE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CYCLOSERINE; DAVUNETIDE; DMX B; DONEPEZIL; DOPAMINE 1 RECEPTOR STIMULATING AGENT; FLUMAZENIL; GALANTAMINE; GLYCINE; GUANFACINE; ISPRONICLINE; LAMOTRIGINE; LORAZEPAM; MK 0877; MODAFINIL; MOOD STABILIZER; NEUROLEPTIC AGENT; NOOTROPIC AGENT; PLACEBO; RIMONABANT; RIVASTIGMINE; TANDOSPIRONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BEHAVIOR MODIFICATION; COGNITIVE DEFECT; COGNITIVE REMEDIATION; COMPUTER PROGRAM; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FUNCTIONAL STATUS; HUMAN; NERVE CELL PLASTICITY; NONHUMAN; OFF LABEL DRUG USE; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; SCHIZOPHRENIA; SOCIAL COGNITION; THERAPY EFFECT;

BEHAVIOR THERAPY; COGNITION DISORDERS; HUMANS; NOOTROPIC AGENTS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84865427240     PISSN: 0193953X     EISSN: 15583147     Source Type: Journal    
DOI: 10.1016/j.psc.2012.06.008     Document Type: Review

References (74)

1. Gold J.M., Harvey P.D. Cognitive deficits in schizophrenia. Psychiatr Clin North Am 1993, 16:295-312.
2. Bowie C.R., Harvey P.D. Cognition in schizophrenia: impairment, determinants, and functional importance. Psychiatr Clin North Am 2005, 28:613-633.
3. Hyman S.E., Fenton W.S. Medicine. What are the right targets for psychopharmacology?. Science 2003, 299:350-351.
4. Marder S.R., Fenton W. Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res 2004, 72:5-9.
5. Nuechterlein K.H., Green M.F., Kern R.S., et al. The MATRICS consensus cognitive battery, part 1: test selection, reliability, and validity. Am J Psychiatry 2008, 165:203-213.
6. Kern R.S., Nuechterlein K.H., Green M.F., et al. The MATRICS consensus cognitive battery: part 2. Co-norming and standardization. Am J Psychiatry 2008, 165:214-220.
7. Green M.F., Nuechterlein K.H., Kern R.S., et al. Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study. Am J Psychiatry 2008, 165:221-228.
8. Moore D.J., Palmer B.W., Patterson T.L., et al. A review of performance-based measures of everyday functioning. J Psychiatr Res 2007, 41:97-118.
9. Patterson T.L., Goldman S., McKibbin C.L., et al. UCSD performance-based skills assessment: development of a new measure of everyday functioning for severely mentally ill adults. Schizophr Bull 2001, 27:235-245.
10. Heaton R.K., Marcotte T.D., Mindt M.R., et al. The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc 2004, 10:317-331.
11. Leifker F.R., Patterson T.L., Heaton R.K., et al. Validating measures of real-world outcome: the results of the VALERO expert survey and RAND Panel. Schizophr Bull 2011, 37:334-343.
12. Bowie C.R., Leung W.W., Reichenberg A., et al. Predicting schizophrenia patients' real world behavior with specific neuropsychological and functional capacity measures. Biological Psychiatry 2008, 63:505-511.
13. Bowie C.R., Depp C., McGrath J.A., et al. Prediction of real-world functional disability in chronic mental disorders: a comparison of schizophrenia and bipolar disorder. American Journal of Psychiatry 2010, 167:1116-1124.
14. Sabbag S., Twamley E.W., Vella L., et al. Assessing everyday functioning in schizophrenia: not all informants seem equally informative. Schizophrenia Research 2011, 131:250-255.
15. Harvey P.D., Penn D. Social cognition: the key factor predicting social outcome in people with schizophrenia?. Psychiatry (Edgmont) 2010, 7:41-44.
16. Eack S.M., Pogue-Geile M.F., Greeno C.G., et al. Evidence of factorial variance of the Mayer-Salovey-Caruso Emotional Intelligence Test across schizophrenia and normative samples. Schizophr Res 2009, 114:105-109.
17. Fett A.K., Viechtbauer W., Dominguez M.D., et al. The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis. Neurosci Biobehav Rev 2011, 35:573-588.
18. Leifker F.R., Bowie C.R., Harvey P.D. The determinants of everyday outcomes in schizophrenia: influences of cognitive impairment, clinical symptoms, and functional capacity. Schizophr Res 2009, 115:82-87.
19. Mayer J.D., Salovey P., Caruso D.R. Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) user's manual 2002, MHS Publishers, Toronto.
20. Ventura J, Wood RC, Hellemann GS. Symptom domains and neurocognitive functioning can help differentiate social cognitive processes in schizophrenia: a meta-analysis. Schizophr Bull, in press.
21. Laughren T. A regulatory perspective on psychiatric syndromes in Alzheimer's disease. Am J Geriatr Psychiatry 2001, 9:340-345.
22. Kahn A. Current evidence for aripiprazole as augmentation therapy in major depressive disorder. Expert Rev Neurother 2008, 8:1435-1447.
23. Buchanan R.W., Davis M., Goff D., et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull 2005, 31:5-19.
24. Buchanan R.W., Keefe R.S., Umbricht D., et al. The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?. Schizophr Bull 2011, 37:1209-1217.
25. Medalia A., Revheim N., Herlands T. Cognitive remediation for psychological disorders, therapist guide 2009, Oxford University Press, New York.
26. Bell B., Bryson G., Wexler B.E. Cognitive remediation of working memory deficits: durability of training effects in severely impaired and less severely impaired schizophrenia. Acta Psychiatr Scand 2003, 108:101-109.
27. Wykes T., Reeder C., Comer J., et al. The effects of neurocognitive remediation on executive processing in patients with schizophrenia. Schizophr Bull 1993, 25:291-307.
28. Brenner H.D., Hodel B., Roder V., et al. Treatment of cognitive dysfunction and behavioral deficits in schizophrenia. Schizophr Bull 1992, 18:21-26.
29. Hogarty G.E., Flesher S., Ulrich R., et al. Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior. Arch Gen Psychiatry 2004, 61:866-876.
30. Velligan D.I., Diamond P.M., Mintz J., et al. The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia. Schizophr Bull 2008, 34:483-493.
31. Twamley E.W., Savla G.N., Zurhellen C.H., et al. Development and pilot testing of a novel compensatory cognitive training intervention for people with psychosis. Am J Psychiatr Rehabil 2008, 11:144-163.
32. Fisher M., Holland C., Subramaniam K., et al. Neuroplasticity-based cognitive training in schizophrenia: an interim report on effects 6 months later. Schizophr Bull 2010, 36:869-879.
33. Popov T., Jordanov T., Rockstroh B., et al. Specific cognitive training normalizes auditory sensory gating in schizophrenia: a randomized trial. Biol Psychiatry 2011, 69:465-471.
34. Wykes T., Brammer M., Mellers J., et al. Effects on the brain of psychological treatment: cognitive remediation therapy: functional magnetic resonance imaging in schizophrenia. Br J Psychiatry 2002, 181:144-152.
35. Vinogradov S., Fisher M., Holland C., et al. Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia?. Biol Psychiatry 2009, 66:549-553.
36. Adcock R.A., Dale C., Fisher M., et al. When top-down meets bottom-up: auditory training enhances verbal memory in schizophrenia. Schizophr Bull 2009, 35:1132-1141.
37. Bosia M., Bechi M., Marino E., et al. Influence of catechol-O-methyltransferase Val158Met polymorphism on neuropsychological and functional outcomes of classic rehabilitation and cognitive remediation in schizophrenia. Neurosci Lett 2007, 417:271-274.
38. Vinogradov S., Fisher M., Warm H., et al. The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am J Psychiatry 2009, 166:1055-1062.
39. Eack S.M., Hogarty G.E., Cho R.Y., et al. Neuroprotective effects of cognitive enhancement therapy against gray matter loss in early schizophrenia: results from a 2-year randomized controlled trial. Arch Gen Psychiatry 2010, 67:674-682.
40. McGurk S.R., Twamley E.W., Sitzer D.I., et al. A meta-analysis of cognitive remediation in schizophrenia. Am J Psychiatry 2007, 164:1791-1802.
41. Wu E.Q., Bimbaum H.G., Shi L., et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005, 66:1122-1129.
42. McGurk S.R., Mueser K.T., DeRosa T.J., et al. Work, recovery, and comorbidity in schizophrenia: a randomized controlled trial of cognitive remediation. Schizophr Bull 2009, 35:319-335.
43. Bell M.D., Zito W., Greig T., et al. Neurocognitive enhancement therapy with vocational services: work outcomes at two-year follow-up. Schizophr Res 2008, 105:18-29.
44. Geyer M.A., Tamminga C.A. Measurement and treatment research to improve cognition in schizophrenia: neuropharmacological aspects. Psychopharmacology 2004, 174:1-2.
45. Harvey P.D. Pharmacological cognitive enhancement in schizophrenia. Neuropsychol Rev 2009, 19:324-335.
46. Keefe R.S.E., Malhotra A.K., Meltzer H.Y., et al. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology 2008, 33:1217-1228.
47. Sharma T.S., Reed C., Aasen I., et al. Cognitive effects of adjunctive 24-week rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation. Schizophr Res 2006, 85:73-83.
48. Buchanan R.W., Conley R.R., Dickinson D., et al. Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry 2007, 165:82-89.
49. Freedman R., Olincy A., Buchanan R.W., et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 2008, 165:1040-1047.
50. Available at: Accessed December 15, 2011. http://www.astrazeneca.com/itemid4376018.
51. Buchanan R.W., Javitt D.C., Marder S.R., et al. The cognitive and negative symptoms in schizophrenia trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 2007, 164:1593-1602.
52. Goff D.C., Lamberti J.S., Leon A.C., et al. A placebo-controlled add-on trial of the ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology 2008, 33:465-472.
53. Friedman J.I., Adler D.N., Temporini H.D., et al. Guanfacine treatment of cognitive impairment in schizophrenia. Neuropsychopharmacology 2001, 25:402-409.
54. Friedman J.I., Carpenter D., Lu J., et al. A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia. J Clin Psychopharmacol 2008, 28:59-63.
55. Buchanan R.W., Keefe R.S., Lieberman J.A., et al. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry 2011, 69:442-449.
56. Sumiyoshi T., Matsui M., Nohara S., et al. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry 2001, 158:1722-1725.
57. Sumiyoshi T., Park S., Jayathilake K., et al. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res 2007, 95:158-168.
58. Boggs D.L., Kelly D.L., McMahon R.P., et al. Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial. Schizophr Res 2012, 134(2-3):207-210.
59. Anand A., Charney D.S., Oren D.A., et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine. Arch Gen Psychiatry 2000, 57:270-276.
60. Zoccali R., Muscatello M.R., Bruno A., et al. The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study. Schizophr Res 2007, 93:109-116.
61. Goff D.C., Keefe R.S.E., Citrome L., et al. Lamotrigine as add-on therapy in schizophrenia results of 2 placebo-controlled trials. J Clin Psychopharmacol 2007, 27:582-589.
62. Morein-Zamir S., Turner D.C., Sahakian B.J. A review of the effects of modafinil on cognition in schizophrenia. Schizophr Bull 2007, 33:1298-1306.
63. Minzenberg M.J., Carter C.S. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 2008, 33:1477-1502.
64. Menzies L., Ooi C., Kamath S., et al. Effects of gamma-aminobutyric acid modulating drugs on working memory and brain function in patients with schizophrenia. Arch Gen Psychiatry 2007, 64:156-167.
65. Javitt D.C., Buchanan R.W., Keefe R.S., et al. Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr Res 2012, 136(1-3):25-31.
66. DeLisi L.E., Szulc K.U., Bertisch H.C., et al. Understanding structural brain changes in schizophrenia. Dialogues Clin Neurosci 2006, 8:71-78.
67. Cahn W., Rais M., Stigter F.P., et al. Psychosis and brain volume changes during the first five years of schizophrenia. Eur Neuropsychopharmacol 2009, 19:147-151.
68. Laruelle M. Dopamine transmission in the schizophrenic brain. Schizophrenia 1999, 365-387. Blackwell, Oxford (United Kingdom). S.R. Hirsch, D.R. Weinberger (Eds.).
69. Arnsten A.F., Cai J.X., Murphy B.L., et al. Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology 1994, 116:143-151.
70. Akbarian S., Kim J.J., Potkin S.G., et al. Maldistribution of interstitial neurons in the prefrontal white matter of brains of schizophrenic patients. Arch Gen Psychiatry 1996, 53:425-436.
71. Lim K.O., Hedehus M., Moseley M., et al. Compromised white matter tract integrity in schizophrenia inferred from diffusion tensor imaging. Arch Gen Psychiatry 1999, 56:367-374.
72. Keefe R.S., Vinogradov S., Medalia A., et al. Report from the Working Group Conference on multi-site trial design for cognitive remediation in schizophrenia. Schizophr Bull 2010, 10.1093/schbul/sub010.
73. Wykes T., Huddy V., Cellard C., et al. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry 2011, 168:472-485.
74. Keefe RS, Vinogradov S, Medalia A, et al. Feasibility and pilot efficacy results from the multi-site Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) study. J Clin Psychiatry, in press.